Skip to main content
. 2025 Oct 22;15:36959. doi: 10.1038/s41598-025-20873-2

Table 2.

Laboratory findings and CIMT values of study groups.

Healthy Control (n = 20) Diabetic Group without complications
(n = 45)
Diabetic Group with Microvascular complications (n = 24) Diabetic Group with Macrovascular complications (n = 20) CAD without DM
(n = 19)
Fasting Blood Glucose (mg/dL) 89 ± 7 163 ± 72 a*** 164 ± 73 a*** 164 ± 49 a*** 96 ± 6 b***, c***, d***
HbA1c (%) 5.6 ± 0.4 7.6 ± 1.9 a*** 7.8 ± 1.5 a*** 7.5 ± 1.2 a*** 5.6 ± 0.4 b***, c***, d***
HOMA-IR 2.3 ± 0.8 6.5 ± 5.9 6.4 ± 4.6 5.3 ± 3.3 13.8 ± 36.3
Total cholesterol (mg/dL) 172 ± 15 205 ± 42 a* 186 ± 46 a* 177 ± 38 b* 194 ± 33 a*
HDL (mg/dL) 52 ± 13 48 ± 14 49 ± 13 44 ± 11 47 ± 10
LDL (mg/dL) 107 ± 17 121 ± 39 105 ± 35 101 ± 31 113 ± 31
Triglyceride (mg/dL)+ 81 (65–98) 193 (140–245) a*** 134 (90–180) a***, b** 172 (120–210) a***, b*,c* 153 (110–195) a***, b*
Creatinine (mg/dl) 0.9 ± 0.1 0.9 ± 0.2 1.2 ± 1.1 0.9 ± 0.3 1 ± 0.1
Creatinine clearance (mL/min) 132 ± 22 129 ± 34 126 ± 45 106 ± 32 a*,b*,c* 108 ± 19 a*,b*
Albumin/creatinine ratio+ 4 (3–5) 14 (8–30) 242 (50–400) 418 (200–700) 5 (4–6)
CRP (mg/L) + 0.9 (0.6–1.2) 6 (3–12) 9.6 (4–15) 2.9 (2.0–4.0) 2.6 (1.8–3.5)
Adropin (ng/L) + 180 ± 39 95 ± 27 a*** 85 ± 18 a*** 75 ± 15 a***, b* 53 ± 8 a***, b***, c***
miR-21+ 15 ± 10 54 ± 13 a*** 74 ± 21 a***, b*** 105 ± 23 a***, b***, c*** 165 ± 22 a***, b***, c***, d***
CIMT (mm) 0.61 ± 0.11 0.95 ± 0.21 1.01 ± 0.26 1 ± 0.2 1.08 ± 0.22

Abbreviations: CIMT = Carotid Intima-Media Thickness; CAD = Coronary Artery Disease; CRP = C-Reactive Protein; HbA₁c = Hemoglobin A₁c.

Statistical tests: Normality was assessed by the Shapiro–Wilk test. Continuous variables with a normal distribution were compared by one-way ANOVA (with Bonferroni-adjusted Tukey post-hoc tests); non-normally distributed variables were compared by the Kruskal–Wallis test and are indicated by an asterisk (+). Categorical variables were compared by the χ² test. A two-tailed p < 0.05 was considered significant.

a: vs. Healthy Control, b: vs. Diabetic Group without complications, c: vs. Diabetic Group with Microvascular complications, d: vs. Diabetic Group with Macrovascular complications, *:p < 0.05, **:p < 0.01, ***:p < 0.001.